Compare SCHL & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | OABI |
|---|---|---|
| Founded | 1920 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 696.4M |
| IPO Year | 1995 | 2021 |
| Metric | SCHL | OABI |
|---|---|---|
| Price | $36.13 | $4.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 381.9K | ★ 1.3M |
| Earning Date | 09-24-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ 3442.86 | 6.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,487,100,000.00 | $18,666,000.00 |
| Revenue This Year | $2.14 | $87.33 |
| Revenue Next Year | $3.42 | $24.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.38 | $1.32 |
| 52 Week High | $48.07 | $5.43 |
| Indicator | SCHL | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 65.70 |
| Support Level | $32.81 | $1.90 |
| Resistance Level | $35.89 | $5.43 |
| Average True Range (ATR) | 1.14 | 0.26 |
| MACD | 0.25 | -0.00 |
| Stochastic Oscillator | 75.14 | 94.62 |
Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.